Aderbasib - Wikiwand
For faster navigation, this Iframe is preloading the Wikiwand page for Aderbasib.

Aderbasib

From Wikipedia, the free encyclopedia

Aderbasib
Clinical data
Routes of
administration
Oral
ATC code
  • None
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H28N4O5
Molar mass416.47 g·mol−1 g·mol−1
3D model (JSmol)

Aderbasib (codenamed INCB7839) is a sheddase inhibitor that may suppress tumor cell proliferation.[1] Acting on multiple receptor classes and subclasses, aderbasib is observed to regulate the tumor necrosis factor of cancer cells.[2] Aderbasib was being developed by Incyte as a potential adjunctive treatment for metastatic breast cancer. Development was halted in 2011 after positive findings from Phase II trials were contradicted by further research.[3][4]

References

  1. ^ "STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL" (PDF). Ama-assn.org. Retrieved 2012-10-13.
  2. ^ "Aderbasib | CAS#791828-58-5". MedKoo. Retrieved 2012-10-13.
  3. ^ Incyte (2011-09-19). "UBS 2011 Global Life Sciences Conference". Retrieved 2013-02-13.
  4. ^ "Incyte Reports Third Quarter 2011 Financial Results And Provides Update On Key Clinical Programs" (Press release). BusinessWire. 2011-10-27. Retrieved 2013-02-13.
{{bottomLinkPreText}} {{bottomLinkText}}
Aderbasib
Listen to this article